Detection of metabolites in the white matter of frontal lobes and hippocampus with proton in first-episode treatment-naïve schizophrenia patients

Early Intervention in Psychiatry

Volumn 6, Issue 2, 2012, Pages 166-175

  He, Zong Ling ^a,b   Deng, Wei ^a,b   Li, Ming Li ^a,b   Chen, Zhuang Fei ^a,b   Collier, David A ^c   Ma, Xiaohong ^a   Li, Tao ^a,b  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Frontal lobe; Hippocampus; Laterality index; Magnetic resonance spectroscopy; Schizophrenia; White matter

Indexed keywords

CHOLINE DERIVATIVE; CREATINE; CREATINE PHOSPHATE; INOSITOL; N ACETYLASPARTIC ACID; PROTON;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FRONTAL LOBE; HIPPOCAMPUS; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLITE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RATING SCALE; SCHIZOPHRENIA; SYMPTOM; WHITE MATTER;

ADULT; ASPARTIC ACID; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHOLINE; CREATINE; DOMINANCE, CEREBRAL; FEMALE; FRONTAL LOBE; HIPPOCAMPUS; HUMANS; INOSITOL; MAGNETIC RESONANCE SPECTROSCOPY; MALE; NERVE FIBERS, MYELINATED; PROTONS; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX;

EID: 84859927262     PISSN: 17517885     EISSN: 17517893     Source Type: Journal    
DOI: 10.1111/j.1751-7893.2011.00291.x     Document Type: Article

References (54)

1. Vance AL, Velakoulis D, Maruff P, Wood SJ, Desmond P, Pantelis C. Magnetic resonance spectroscopy and schizophrenia: what have we learnt? Aust N Z J Psychiatry 2000; 34: 14-25.
2. Gujar SK, Maheshwari S, Björkman-Burtscher I, Sundgren PC. Magnetic resonance spectroscopy. J Neuroophthalmol 2005; 25: 217-26.
3. Lu ZH, Chakraborty G, Ledeen RW, Yahya D, Wu G. N-acetylaspartate synthase is bimodally expressed in microsomes and mitochondria of brain. Mol Brain Res 2004; 122: 71-8.
4. Auer DP, Wilke M, Grabner A, Heidenreich JO, Bronisch T, Wetter TC. Reduced NAA in the thalamus and altered membrane and glial metabolism in schizophrenic patients detected by 1H-MRS and tissue segmentation. Schizophr Res 2001; 52: 87-99.
5. Connelly A, Jackson GD, Duncan JS, King MD, Gadian DG. Magnetic resonance spectroscopy in temporal lobe epilepsy. Neurology 1994; 44: 1411-7.
6. Ngür D, Prescot AP, Jensen JE, Cohen BM, Renshaw PF. Creatine abnormalities in schizophrenia and bipolar disorder. Psychiatry Res 2009; 172: 44-8.
7. Silverstone PH, McGrath BM, Kim H. Bipolar disorder and myo-inositol: a review of the magnetic resonance spectroscopy findings. Bipolar Disord 2005; 7: 1-10.
8. Kirkpatrick B, Buchanan RW, McKenny PD, Alphs LD, Carpenter WT. The schedule for the deficit syndrome: an instrument for research in schizophrenia. Psychiatry Res 1989; 30: 119-23.
9. Makris N, Seidman LJ, Ahern T etal. White matter volume abnormalities and associations with symptomatology in schizophrenia. Psychiatry Res 2010; 183: 21-9.
10. Dean B, Boer S, Gibbons A, Money T, Scarr E. Recent advances in postmortem pathology and neurochemistry in schizophrenia. Curr Opin Psychiatry 2009; 22: 154-60.
11. Hof PR, Haroutunian V, Friedrich VL. Loss and altered spatial distribution of oligodendrocytes in the superior frontal gyrus in schizophrenia. Biol Psychiatry 2003; 53: 1075-85.
12. Manns JR, Hopkins RO, Reed JM, Kitchener EG, Squire LR. Recognition memory and the human hippocampus. Neuron 2003; 37: 171-80.
13. Schultz CC, Koch K, Wagner G etal. Reduced cortical thickness in first episode schizophrenia. Schizophr Res 2009; 116: 204-9.
14. Reynolds GP. Post-mortem neurochemistry of schizophrenia. Psychol Med 2009; 18: 793-7.
15. Minzenberg MJ, Laird AR, Thelen S, Carter CS, Glahn DC. Meta-analysis of 41 functional neuroimaging studies of executive function in schizophrenia. Arch Gen Psychiatry 2009; 66: 811-22.
16. Cullen TJ, Walker MA, Eastwood SL, Esiri MM, Harrison PJ, Crow TJ. Anomalies of asymmetry of pyramidal cell density and structure in dorsolateral prefrontal cortex in schizophrenia. Br J Psychiatry 2006; 188: 26-31.
17. Annett M. A classification of hand preference by association analysis. Br J Psychol 1970; 61: 303-21.
18. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders. Washington, DC: American Psychiatric Press, 1997.
19. Kay SR, Fiszbein A, Opler LA, Id P. Positive and negative syndrome scale. Schizophrenia Bulletin 1987; 13: 261-76.
20. Schuff N, Ezekiel F, Gamst AC etal. Region and tissue differences of metabolites in normally aged brain using multislice 1H magnetic resonance spectroscopic imaging. Magn Reson Med 2001; 45: 899-907.
21. Jensen JE, Miller J, Williamson PC etal. Grey and white matter differences in brain energy metabolism in first episode schizophrenia: 31P-MRS chemical shift imaging at 4 Tesla. Psychiatry Res 2006; 146: 127-35.
22. Kegeles LS, Shungu DC, Anjilvel S etal. Hippocampal pathology in schizophrenia: magnetic resonance imaging and spectroscopy studies. Psychiatry Res: Neuroimaging 2000; 98: 163-75.
23. Shenton ME, Dickey CC, Frumin M, McCarley RW. A review of MRI findings in schizophrenia. Schizophr Res 2001; 49: 1-52.
24. Ornstein TJ, Sahakian BJ, McKenna PJ. Memory and executive impairment in schizophrenia: comparison with frontal and temporal brain damage. Psychol Med 2008; 38: 833-42.
25. Wood SJ, Berger G, Velakoulis D etal. Proton magnetic resonance spectroscopy in first episode psychosis and ultra high-risk individuals. Schizophr Bull 2003; 29: 831-43.
26. Ohrmann P, Siegmund A, Suslow T etal. Evidence for glutamatergic neuronal dysfunction in the prefrontal cortex in chronic but not in first-episode patients with schizophrenia: a proton magnetic resonance spectroscopy study. Schizophr Res 2005; 73: 153-7.
27. Galinska B, Szulc A, Tarasow E etal. Duration of untreated psychosis and proton magnetic resonance spectroscopy (1H-MRS) findings in first-episode schizophrenia. Med Sci Monit 2009; 15: CR82-88.
28. Szulc A, Galinska B, Tarasow E etal. Clinical and neuropsychological correlates of proton magnetic resonance spectroscopy detected metabolites in brains of first-episode and schizophrenic patients. Psychiatr Pol 2003; 37: 977-88.
29. Fannon D, Simmons A, Tennakoon L etal. Selective deficit of hippocampal N-acetylaspartate in antipsychotic-naive patients with schizophrenia. Biol Psychiatry 2003; 54: 587-98.
30. Tunc-Skarka N, Weber-Fahr W, Hoerst M, Meyer-Lindenberg A, Zink M, Ende G. MR spectroscopic evaluation of N-acetylaspartate's T2 relaxation time and concentration corroborates white matter abnormalities in schizophrenia. Neuroimage 2009; 48: 525-31.
31. Nagae-Poetscher LM, Bonekamp D, Barker PB, Brant LJ, Kaufmann WE, Horská A. Asymmetry and gender effect in functionally lateralized cortical regions: a proton MRS imaging study. J Magn Reson Imaging 2004; 19: 27-33.
32. Weber-Fahr W, Busch MG, Finsterbusch J. Short-echo-time magnetic resonance spectroscopy of single voxel with arbitrary shape in the living human brain using segmented two-dimensional selective radiofrequency excitations based on a blipped-planar trajectory. Magn Reson Imaging 2009; 27: 664-71.
33. Steen RG, Hamer RM, Lieberman JA. Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis. Neuropsychopharmacology 2005; 30: 1949-62.
34. Shirayama Y, Obata T, Matsuzawa D etal. Specific metabolites in the medial prefrontal cortex are associated with the neurocognitive deficits in schizophrenia: a preliminary study. Neuroimage 2009; 49: 2783-90.
35. Sanches RF, Crippa JA, Hallak JE etal. Proton magnetic resonance spectroscopy of the frontal, cingulate and perirolandic cortices and its relationship to skin conductance in patients with schizophrenia. Braz J Med Biol Res 2008; 41: 1132-41.
36. Tang CY, Friedman J, Shungu D etal. Correlations between Diffusion Tensor Imaging (DTI) and Magnetic Resonance Spectroscopy (1H MRS) in schizophrenic patients and normal controls. BMC Psychiatry 2007; 7: 25.
37. Basoglu C, Cetin M, Oner O etal. Comparison of right thalamus and temporal cortex metabolite levels of drug-naive first-episode psychotic and chronic schizophrenia in patients. Turk Psikiyatri Derg 2006; 17: 85-91.
38. Chang HM, Qi ST, Yang KJ, Wang KW, Guo ZW, Wang H. Proton magnetic resonance spectroscopic imaging of the hippocampus in schizophrenia patients before and after surgery. Nan Fang Yi Ke Da Xue Xue Bao 2009; 29: 996-8.
39. Yang JM, Jiang ZK, Gan JL etal. (1) H-MRS study of prefrontal lobe in patients with schizophrenia. Yixue Yingxiangxue Zazhi (J Med Imaging) 2009; 19: 1078-81.
40. Ohrmann P, Siegmund A, Suslow T etal. Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: a proton magnetic resonance spectroscopy study. J Psychiatr Res 2007; 41: 625-34.
41. Szulc A. First and second generation antipsychotics and morphological and neurochemical brain changes in schizophrenia. Review of magnetic resonance imaging and proton spectroscopy findings. Psychiatr Pol 2007; 41: 329-38.
42. Wood SJ, Berger GE, Wellard RM etal. A 1H-MRS investigation of the medial temporal lobe in antipsychotic-naive and early-treated first episode psychosis. Schizophr Res 2008; 102: 163-70.
43. Oertel V, Knochel C, Rotarska-Jagiela A etal. Reduced laterality as a trait marker of schizophrenia - evidence from structural and functional neuroimaging. J Neurosci 2010; 30: 2289-99.
44. Moore CM, Bonello CM, Sherwood AR, Cohen BM, Renshaw PF, Yurgulen-Todd DA. Mesial temporal lobe Cho to Cr(PCr) ratio asymmetry in chronic schizophrenics. Schizophr Res 2002; 57: 35-42.
45. Tanaka Y, Obata T, Sassa T etal. Quantitative magnetic resonance spectroscopy of schizophrenia: relationship between decreased N-acetylaspartate and frontal lobe dysfunction. Psychiatry Clin Neurosci 2006; 60: 365-72.
46. Sigmundsson T, Maier M, Toone BK etal. Frontal lobe N-acetylaspartate correlates with psychopathology in schizophrenia: a proton magnetic resonance spectroscopy study. Schizophr Res 2003; 64: 63-71.
47. Truckenmiller ME, Namboodiri MAA, Brownstein MJ, N NJH. Acetylation of L-aspartate in the nervous system: differential distribution of a specific enzyme. J Neurochem 2006; 45: 1658-62.
48. Tullberg M, Fletcher E, DeCarli C etal. White matter lesions impair frontal lobe function regardless of their location. Neurology 2004; 63: 246.
49. Bertolino A, Sciota D, Brudaglio F etal. Working memory deficits and levels of N-acetylaspartate in patients with schizophreniform disorder. Am J Psychiatry 2003; 160: 483-9.
50. Rango M, Spagnoli D, Tomei G, Bamonti F, Scarlato G, Zetta L. Central nervous system trans-synaptic effects of acute axonal injury: a 1H magnetic resonance spectroscopy study. Magn Reson Med 2005; 33: 595-600.
51. Degaonkar MN, Khubchandhani M, Dhawan JK, Jayasundar R, Jagannathan NR. Sequential proton MRS study of brain metabolite changes monitored during a complete pathological cycle of demyelination and remyelination in a lysophosphatidyl choline (LPC)-induced experimental demyelinating lesion model. NMR Biomed 2002; 15: 293-300.
52. Choe BY, Suh TS, Shinn KS, Lee CW, Lee C, Paik IH. Observation of metabolic changes in chronic schizophrenia after neuroleptic treatment by in vivo hydrogen magnetic resonance spectroscopy. Invest Radiol 1996; 31: 345-52.
53. Soares DP, Law M. Magnetic resonance spectroscopy of the brain: review of metabolites and clinical applications. Clin Radiol 2009; 64: 12-21.
54. Boulanger Y, Labelle M, Khiat A. Role of phospholipase A2 on the variations of the choline signal intensity observed by 1H magnetic resonance spectroscopy in brain diseases1. Brain Res Rev 2000; 33: 380-9.